Abstract 244P
Background
Taxane-based therapy is commonly applied in patients with advanced breast cancer (BC). It is often accompanied with serious symptomatic adverse events (AEs) which can deteriorate patients’ quality of life (QoL). Eribulin is a non-taxane microtubule inhibitor with respect to less symptomatic AEs and prolonged overall survival. Here, we report the analysis of QoL based on PRO before and after initiating Eribulin in patients with advanced BC intolerant to taxane-based therapy.
Methods
Patients with advanced BC intolerant to taxane-based first/second-line therapy were screened from multi-centers in China. The PRO was measured by the well-validated taxane-based EORTC QLQ-C30 questionnaire at baseline and at 2 cycles after initialing Eribulin treatment. The questionnaire includes scales for four symptomatic AEs of microtubule therapy (peripheral neurotoxicity, nausea/vomiting, pain, insomnia) and a global health status for QoL (GHS/QoL).
Results
Of the 333 enrolled patients, 152 with triple-negative BC, 122 with HR+/HER2- BC, and 59 with HER2+ BC. Significant improvement in all symptomatic AEs and the GHS/QoL (P<0.001) was observed among all patients and the subgroups of the pathological type. Respectively, there were 116 and 73 patients received only combined chemotherapy and mono-chemotherapy both before (taxane-based) and 2 cycles after (Eribulin-based) the treatment. Subgroup analysis showed all symptoms and the GHS/QoL were significantly improved in both treatment settings (P<0.001).
Conclusions
The measurements for PRO indicated great improvement on QoL after switching to Eribulin in patients with advanced BC who previously received taxane-based therapy, irrespective of the pathological type and the combination of other chemotherapy regimens. Eribulin is reasonable to be applied in patients with advanced BC intolerant to taxane-based therapy. Table: 244P
| Dimensions | Baseline | Post-treatment | P |
| Peripheral neurotoxicity | 57.9±20.3 | 34.3±15.6 | <0.001 |
| Nausea/vomiting | 58.0±20.7 | 34.5±16.3 | <0.001 |
| Insomnia | 58.2±20.2 | 35.1±19.1 | <0.001 |
| Pain | 56.1±20.0 | 35.9±15.5 | <0.001 |
| Global health status | 33.7±22.5 | 58.3±29.4 | <0.001 |
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.